Trevena (NASDAQ:TRVN) Now Covered by StockNews.com

Stock analysts at StockNews.com started coverage on shares of Trevena (NASDAQ:TRVN) in a research report issued to clients and investors on Tuesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “neutral” rating and issued a $5.00 price objective on shares of Trevena in a research note on Thursday, November 14th.

Trevena Price Performance

TRVN opened at $1.68 on Tuesday. Trevena has a 12 month low of $1.13 and a 12 month high of $19.23. The stock has a market capitalization of $1.45 million, a P/E ratio of -0.04 and a beta of 1.08. The business has a 50 day simple moving average of $3.05 and a 200-day simple moving average of $5.58.

Trevena (NASDAQ:TRVN) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) EPS for the quarter. The business had revenue of $0.28 million during the quarter. Research analysts anticipate that Trevena will post -23.04 EPS for the current year.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.